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Abstract
Background: Mouse models of human disease are invaluable for determining the differentiation ability and functional
capacity of stem cells. The best example is bone marrow transplants for studies of hematopoietic stem cells. For organ
studies, the interpretation of the data can be difficult as transdifferentiation, cell fusion or surface antigen transfer
(trogocytosis) can be misinterpreted as differentiation. These events have not been investigated in hematopoietic stem cell
transplant models.
Methodology/Principal Findings: In this study we investigated fusion and trogocytosis involving blood cells during bone
marrow transplantation using a xenograft model. We report that using a standard SCID repopulating assay almost 100% of
the human donor cells appear as hybrid blood cells containing both mouse and human surface antigens.
Conclusion/Significance: Hybrid cells are not the result of cell-cell fusion events but appear to be due to efficient surface
antigen transfer, a process referred to as trogocytosis. Antigen transfer appears to be non-random and includes all donor
cells regardless of sub-type. We also demonstrate that irradiation preconditioning enhances the frequency of hybrid cells
and that trogocytosis is evident in non-blood cells in chimera mice.
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Introduction
Stem cell biology relies heavily on the specificity of surface
markers as an initial determination of a cells identity after
differentiation. Presentation of a predetermined set of markers
characteristic of the desired cell type being investigated is required
before more complex studies to determine cell function are carried
out. In vitro studies can be used to determine cell function but the
ability of a newly differentiated cell to successfully reverse the
affects of a disease in an experimental animal model is the gold
standard. Being able to identify donor cells in any animal model is
critical for determining the extent and the mechanism of
engraftment and differentiation.
Mouse models for bone marrow transplantation with hemato-
poietic stem cells (HSC) have become the paradigm for stem cells
analysis since their discovery almost 50 years ago [1,2]. With the
discovery of embryonic and tissue specific stem cells, mouse
models of disease are also often used to measure the differentiation
and functional capacity of these cells. As with HSC transplants,
embryonic or tissue specific stem cells are delivered to the diseased
organ and successful engraftment and restoration of tissue function
is measured post transplantation [3,4,5,6]. Both intraspecies and
xenograft models of disease have been successfully used to
demonstrate the functional capacity of different types of human
and mouse stem cells. Additionally, mouse models of human
disease are ideal for determining the clinical significance of novel
stem cell based therapies due to the incidence of similar
transplantation issues that occur in a clinical setting such as graft
rejection and, for bone marrow transplants, graft versus host
disease (GvHD) [7,8,9,10].
The analysis of HSC engraftment in most cases is straightforward
because the donor cells can be easily recovered from the bone
marrow as single cells and their contribution is measured by
antibodies to donor specificcell surface proteins using flow cytometry.
For solid organ transplants such as pancreas, spinal cord or heart, the
delivery of cells and their subsequent identification and recovery after
transplantation is more complex. Usually, immunohistochemical
analysis of solid organs is required. The difficulty of obtaining high
levels of engraftment, coupled with the difficulty of tissue recovery
and analysis results in few positive events. Further complicating the
interpretation of the data is that differentiation events in animal
models have been attributed to differentiation, transdifferentiation,
cell fusion or surface antigen transfer (trogocytosis), depending on the
donor cells and the animal model being used.
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antigen transfer plays a role in hematopoietic cell differentiation in
NOD.CB17-Prkdc
SCID (NOD/SCID) mouse models. Using a
standard SCID repopulating assay, we transplanted irradiated
NOD/SCID mice with either the total nucleated cell (TNC)
population or the donor blood cells were separated into Lineage
positive (mature) cells or the Lineage minus (stem and progenitor)
cells. The blood cells used were from human umbilical cord blood
or human bone marrow. The use of human cells allowed us to
distinguish between human cells (HLA:ABC+) and mouse cells
(H2Kd+). Hybrid cells would be positive for both human and
mouse antigens [11,12].
Cell fusion involves the fusion of cell membranes, cytoplasm and
the nuclei resulting in a hybrid cell that contains chromosomes and
proteins from both cells [13]. Trogocytosis involves only the
transfer of cell surface antigens without the transfer of DNA or
cytoplasm and transdifferentiation is defined as the ability of a
differentiated cell to change phenotype to an unrelated cell
without undergoing a de-differentiation step [14,15]. In order to
differentiate between cell fusion, trogocytosis or transdifferentia-
tion it is important to investigate the chromosome content and the
surface antigen composition of the cell. Xenograft models are ideal
for determining the extent of these three possible processes during
blood cell engraftment and differentiation. Analysis of fusion or
trogocytosis will result in a mix of human and mouse components
in a single cell, while transdifferentiation will not.
Despite the long time use of bone marrow transplants in both
the clinical and experimental setting, fusion or trogocytosis
between blood cells has not been well documented. In contrast,
cell fusion has been well studied in transplantation models used to
explore the possible transdifferentiation of blood cells [16,17,18].
Moreover, trogocytosis has not been considered in the stem cell
field mainly because its mechanism is unknown and its significance
has been limited to antigen presentation involved in immune
reactions [19,20,21,22].
Our results reveal that the majority of engrafted human cells are
indeed hybrid cells that are a result of surface antigen transfer
(trogocytosis) and not cell-cell fusion. Furthermore our results
demonstrate that trogocytosis is much more widespread than
previously thought resulting in the transfer of host (mouse) MHC
Class I and CD45 antigens to donor (human) cells. We discuss the
implications of these results on the interpretation of blood cell
based therapies to treat blood and non-blood disorders.
Results
Xenograft Bone Marrow Transplants Results in
H2Kd+HLA+ Hybrid Cells
Irradiation of mice followed by intravenous infusion of human
hematopoietic stem cells is a common model for the study of bone
marrow transplantation. The use of immune compromised mice
such as the NOD/SCID mouse allows for successful xenografts
and has been instrumental in the development of bone marrow
transplant regimes for use in patients. With reports that blood cells
are capable of fusing with cells of the liver, Purkinje cells and lung
cells [23], we sought to determine if blood cells are also capable of
fusing amongst themselves. We also wanted to determine the
extent of trogocytosis between donor and recipient cells in a
xenograft model as this process can be interpreted as a cell fusion
event. The xenograft model is ideal for this study as human and
mouse blood antigens can easily be distinguished using flow
cytometry with species specific antibodies to MHC class I or HLA
antigens followed by FISH with mouse and human specific pan-
centromeric probes. Flow cytometry allowed us to detect double
positive cells even if their occurrence was rare. In this study we
report on the results from 119 mice. TNCs, Lin- or Lin+ cells from
human umbilical cord blood or human bone marrow were used
for our xenograft studies. NOD/SCID mice were prepared and
transplanted as per standard protocols [11,24,25]. Our standard
engraftment time of 8–10 weeks was used in the preliminary set of
results. Mice were transfused with 3.5–8 million TNCs or 150,000
Lin- cells or 150,000 Lin+ cells. Mice were assessed at 1 week post
transplantation to 7 months post transplantation. All mice were
assessed for human cells using an antibody against the human
leukocyte antigens-A,B,C (HLA) and mouse cells using an
antibody to the mouse MHC H2Kd (H2kd) antigen that is
specific for NOD/SCID mice. 88% of the umbilical cord blood
(UCB) -transplanted mice (76/86) were positive for HLA+ cells
and all of these positive mice (76/76) contained hybrid cells
(H2Kd+HLA+) (Figure 1A). IgG negative controls (mouse: TNC,
2 months) and sham treated mice (mouse: HBSS, 2 months) were
always negative for HLA antibody reactions (n=8) (Figure 1B).
Mice that received Lin+ cells (n=12) were also negative for HLA-
ABC staining. For all positively engrafted animals except one,
.80% of the human cells (HLA+) isolated from the recipient
mouse bone marrow co-expressed mouse H2Kd antigen
(HLA+H2Kd+). One mouse transplanted with human UCB cells
and assayed at 5 months had a high level of human blood cell
engraftment (82%) and was the only mouse where the majority of
human cells did not also contain the mouse H2Kd antigen. It is
possible that the high percentage of human cells meant that the
mouse cells available for fusion or trogocytosis were limited.
Human bone marrow was also tested using the same transplant
conditions (n=13), with mice assessed at 1 and 2 months.
Engraftment occurred in 11/13 mice and hybrid cells were also
observed in all engrafted mice (representative mouse: Figure 1A,
last panel, 2 month data).
The H2Kd and HLA-ABC antibodies used in this study were
tested for cross species reactions and non-specific reactions using
either mouse BM or human UBC blood or a 50:50 mixture of
mouse and human blood cells (Figure S1). Results indicate that the
anti-HLA antibody only bound human cells while the anti-H2Kd
antibody only bound mouse cells as expected. All other mouse or
human specific antibodies used in this study were also tested for
non-specific binding and demonstrated species specificity (data not
shown).
FISH Analysis Reveals That Trogocytosis and Not Fusion
Occurs between Human and Mouse Blood Cells in the
Xenograft Model and That the Transfer of HLA/MHC Class
I Antigens Is Unidirectional
The observation of such high levels of hybrid cells post
engraftment was unexpected. Our hypothesis was that fusion or
antigen transfer between blood cells may occur but we did not
expect to observe nearly 100% involvement of the donor cells.
Therefore, we sought to confirm if the mechanism is cell fusion
and/or trogocytosis through fluorescent in situ hybridization
(FISH). Pan-centromeric species-specific probes were used to
ensure the random loss of some chromosomes that can occur in
cell hybrids would not produce a false negative result. Post
transplant bone marrow cells that were HLA+H2Kd+ (hybrid)
HLA+H2Kd- (human only) or HLA-H2Kd+ (mouse only) were
collected by FACS and subjected to FISH (Figure 2). The hybrid
cells (H2Kd+HLA+) and the cells with HLA but not H2Kd,
contained only human chromosomes and the non-hybrid mouse
cells (H2Kd+HLA-) from the same mice were positive for mouse
chromosomes only. Mouse bone marrow and human UCB cells
MHC Transfer in BM Transplants
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species specific and that no cross reaction or non-specific reactions
occurred. Karyotyping of the H2Kd+HLA+ cells confirmed our
FISH results that only human chromosomes were present (data
not shown).
The positive results we obtained showing the presence of both
human and mouse surface antigens without the presence of mouse
chromosomes strongly indicate that cell surface antigens are
capable of transferring from one cell to another. Our FISH results
confirm that trogocytosis is unidirectional as the H2Kd+HLA+
hybrid cells only contained human chromosomes. This result
shows that the human cells acquired mouse surface proteins
through trogocytosis. If trogocytosis also occurred in the other
direction (human antigens to mouse cells) then we would have
observed hybrid cells containing mouse chromosomes. Taken
together, this data demonstrates that the donor human cells
Figure 1. Engrafted human cells express mouse H2Kd class I antigens. (A) Flow cytometry results from mice engrafted with human blood
cells analysed at different times post-transplantation. Cells were analysed by FACS with anti-H2Kd-PE antibody to identify mouse MHC-class I proteins
and anti HLA-ABC-FITC antibody to identify human HLA class I proteins. The majority of human cells found in positively engrafted animals were
double positive for H2Kd and HLA-ABC. The Lin+ population are non-engrafting mature blood cells while the Lin- population are enriched for
hematopoietic stem cells. TNC are the unfractionated leukocyte population. (B) i) IgG negative control. ii) Mouse injected with HBSS/no cells followed
by bone marrow analysis after 8-weeks using the same antibodies used to detect human cell HLA and mouse cell H2Kd. The HLA antibody does not
cross react with mouse cells.
doi:10.1371/journal.pone.0008489.g001
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and not fusion.
CD45 Is Involved in Trogocytosis and Is Capable of Bi-
Directional Transfer
Since the bone marrow contains mostly CD45+ blood cells, it is
conceivable that the CD45 antigen may be involved in
trogocytosis. Although the bone marrow is comprised mainly of
CD45+ blood cells we cannot assume that all of the HLA+H2Kd+
hybrid cells are also CD45+. A subset of the mice engrafted with
human blood cells that were analysed for HLA+H2Kd+ cells were
also examined for mouse CD45 and human CD45 to determine if
these surface antigens are involved in trogocytosis. In the previous
experiments we determined that H2kd is transferred to the donor
human cells but there is no reciprocal transfer with HLA to mouse
cells. For the experiments done here, the bone marrow cells from
engrafted mice were stained with H2Kd-PE, HLA-FITC and
Figure 2. Confirmation of trogocytosis. Pan-centromeric probes were used to detect the presence of mouse and human chromosomes in the
H2Kd+/HLA+ cells to ascertain the occurrence of fusion. FACS-sorted cells from an engrafted mouse were analysed by FISH while DAPI identified all
nuclei. HLA+H2Kd+ and HLA+H2Kd- cells tested positive for human chromosomes and negative for mouse chromosomes. FISH results from FACS-
sorted HLA-H2Kd+ cells from the same mouse demonstrated these cells contain only mouse chromosomes and not human chromosomes. These
results confirm that trogocytosis rather than fusion between cells was the cause of the hybrid cells and this also confirms that HLA/MHC Class I
protein is transferred in the recipient to donor direction only. Scale bar=5 mm
doi:10.1371/journal.pone.0008489.g002
MHC Transfer in BM Transplants
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8489CD45-APC (either mouse or human) (n=16 with UCB and n=8
with human bone marrow: 1–4 months post transplantation). All
mice studied showed similar results. The representative data in
Figure 3 was from a mouse that received UCB TNC and was
analysed 2 months post transplantation. This mouse has 15%
HLA+ cells of which 12% are H2Kd+HLA+ (Figure 3Ai). We
observed that only 2% of the HLA positive cells were also mouse
CD45+ (Figure 3Aii) and these cells are also positive for H2Kd
(H2Kd+HLA+mouseCD45+) (Figure 3Aiii). Since H2Kd is
transferred to human cells at a high frequency, these
H2Kd+HLA+mouse CD45+ cells are most likely due to both
mouse CD45 and H2Kd being transferred to the human cells and
that mouse CD45 transfer occurs at a much lower frequency than
for H2Kd.
When the bone marrow cells from the same mouse was stained
for human CD45 we observed more human CD45+ cells than
HLA+ cells (20% versus 15%) (Figure 3Bi) indicating that some of
the human CD45+ cells must be HLA negative. This was
confirmed when the same bone marrow cells interrogated for
human CD45 and HLA. Approximately 4% of the human CD45+
cells were HLA negative (Figure 3Bii). HLA+humanCD45+ cells
were investigated for H2Kd revealing that 91% were triple
positive (Figure 3Biii) confirming that H2Kd is transferred to the
human blood cells. When the 4% HLA- humanCD45+ cells were
examined for the presence of H2Kd antibody, we could
demonstrate that 98% of these cells have H2Kd on their surface
(Figure 3Biv). There are two possible explanations for our
observation. It is possible that H2Kd transferred to the huCD45
cells and at the same time these cells lost their HLA antigens but
this is unlikely and the more parsimonious explanation is that
human CD45 is capable of transferring to mouse bone marrow
cells. Taken together the data reveals that CD45 is capable of bi-
directional transfer although at a low frequency.
Bone marrow cells from mice engrafted with human cells were
simultaneously stained with anti-mouseCD45 and anti-hu-
manCD45. Cells that were mouseCD45+humanCD45- versus
mouseCD45+human CD45+ had higher PE- fluorescent intensity
(mouseCD45: Y-axis) indicating that they contained more mouse
CD45 antigen/cell (Figure 3Ci). Because fluorescence intensity is
directly proportional to the amount of antigen on the cell surface,
this suggests that the hybrid cells (mouseCD45+humanCD45+)
will regulate their total CD45 antigen levels by down regulating
mouse CD45 due to the presence of human CD45 on the surface.
A similar result was observed for peripheral blood cells
(Figure 3Cii).
Trogocytosis Is Not Due to Donor Macrophages
Trogocytosis has been reported to involve antigen presenting
cells such as macrophages. Therefore, we investigated the extent
that macrophages, which express CD14, may contribute to our
observations. No HLA+ or human CD14+ cells were detected in
non-engrafted mice (negative control) (Figures 4Ai, Aii). Mouse
CD14+ cells were observed as expected (Figure 4Aiii). In positively
engrafted mice double positive H2Kd+HLA+ bone marrow cells
were observed (Figure 4Bi). When the bone marrow from these
mice were co-stained for H2Kd and human CD14, all of the
human CD14+ cells were also positive for H2Kd antigen as
expected as H2Kd transfers readily to the human cells
(Figure 4Bii). Since the humanCD14+H2Kd+ cells represent a
subset comprising only 7.2% of the of the hybrid cells
(H2kd+HLA+), this indicates that phagocytosis by human
macrophages are not solely responsible for the high rate of
H2Kd+/HLA+ hybrid cells observed in the grafts. However, we
cannot discount that macrophage phagocytosis is not the
mechanism responsible for the appearance of this small subset of
huCD14+/H2Kd+ hybrid cells. Figure 4Biii reveals that none of
the HLA+ cells were positive for mouse CD14 indicating that
mouse CD14 is not transferred to human cells.
Platelets Are Not Involved in Trogocytosis Events
Previous studies have indicated that trogocytosis is specific to T-
cells and antigen presenting cells, yet the data presented in this
study indicates that many different blood cells are involved. We
investigated if platelets are involved in the trogocytosis in our
model by investigating if the CD41a antigen is transferred from
the recipient cells to donor cells. Platelets are a fairly abundant cell
type found in the bone marrow and should provide sufficient
antigen (CD41a) to be involved in trogocytosis. Using the same
mice used for CD14 detection, mouse CD41a+ cells were detected
in the non-engrafted mouse (negative control) but no HLA+ cells
were present, as expected (Figure 4Ci). However, engrafted mice
did not contain any human CD41a+ cells (Figure 4Cii), indicating
the human UCB cells were not capable of differentiating into
platelets in our SRC assay. Therefore, we could not conclude if
H2Kd is transferred to human platelets. Engrafted mice stained
with antibodies to HLA and mouse CD41a indicate that as
observed for mouse CD14, mouse CD41a does not transfer to
human cells as no double positive cells were observed
(Figure 4Ciii). This result suggests that not all recipient blood
cells are involved and that trogocytosis is regulated in the
xenograft model rather than occurring due to the close association
of randomly paired cells.
Location and Timing of Trogocytosis Indicates a Role for
the Bone Marrow and Reveals the Involvement of
Hematopoietic Stem and Progenitor Cells
In this report all donor cells were injected into the tail vein of
the mice, which requires migration of these cells to the bone
marrow in order to achieve long-term engraftment. It is possible
that the donor cells encounter recipient cells in the peripheral
blood (PB) where trogocytosis could occur between mature blood
cells. In order to determine if the PB is the location of trogocytosis,
we analysed peripheral blood from a subset of the animals
presented in Figure 1. We tested animals transplanted with Lin-
cells or Lin+ cells and could not detect human cells (HLA+) in the
peripheral blood at 7 or 9 days post transplantation, but were able
to observe human cells in the PB from 1 month to 7 months post
transplantation mice (Figure 5A). The PB results for the 1–
7 month post transplantation group were identical to that
observed with their bone marrow cell analysis (Compare to
Figure 1). The absence of human cells or hybrid cells in the PB of
animals given Lin- or Lin+ cells at days 7 and day 9 post
transplantation suggests that trogocytosis does not occur in the
peripheral blood. Coupled with the observation that when the
Lin+ are transplanted no hybrid cells are ever observed, suggests
the trogocytosis occurs in the bone marrow.
Because trogocytosis occurs after the migration of donor cells to
the bone marrow, this suggests stem and progenitor cell
involvement. We tested for this using FACS, CFU and LTC-IC
assays. First, we tested for the transfer of H2Kd to human CD34+
cells in engrafted NOD/SCID mice. Human CD34+ cells in the
SCID repopulating assay represent a rare population. 4-months
post transplantation bone marrow was flushed from a mouse
transplanted with 1610
8 human TNC cells. The mouse was
positive for human CD34+
hi cells (0.14%) and 89% of these cells
were also H2Kd+ indicating the transfer of mouse H2Kd to
human CD34+ cells (Figure 5B).
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flow cytometry. (Ai) A representative mouse demonstrated ,15% HLA+ cells within the bone marrow with the majority also being H2Kd+. (Aii) 2% of
the HLA positive cells were also mouse CD45+ indicating that mouse CD45 does transfer to human cells although at a lower frequency than H2Kd.
(Aiii) The HLA+mouseCD45+ cells were also positive for H2Kd+ (H2Kd+HLA+mouseCD45+). The FISH data confirmed that H2Kd transfers to human
cells but HLA does not transfer to mouse cells, therefore, these triple positive cells arise from the co-transfer of mouse CD45 and H2Kd to human cells.
(Bi) From the same mouse there were more human CD45+ cells (20%) then HLA+ cells (15%) indicating that some of the human CD45+ cells are HLA
negative. (Bii) Double staining for human CD45 and HLA revealed that 4% of the CD45+ cells were HLA negative. (Biii) 91% of the HLA+humanCD45+
cells were also positive for H2Kd. (Biv) Similarly, 96% of the HLA-humanCD45+ cells were also positive for H2Kd. Because of the high level of transfer
of H2Kd to the human cells in the graft the data indicates that both human and mouse CD45 are involved in bi-directional trogocytosis. (C) Co-
staining (i) Bone marrow cells and (ii) Peripheral blood cells from an engrafted mouse with mouseCD45 and humanCD45 antibodies revealed that the
double stained cells contained reduced levels of mouse CD45 versus the mouse cells that were negative for human CD45. It is possible that hybrid
cells can utilize both species of CD45 and regulate the levels in order to maintain cell homeostasis.
doi:10.1371/journal.pone.0008489.g003
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progenitor cells are part of the hybrid cell (H2Kd+HLA+)
population and also allowed us to confirm that trogocytosis and
not cell fusion is the means for hybrid cell production. It is possible
that a cell-cell fusion event could result in the translocation of the
mouse H2Kd gene to a human chromosome, which results in the
expression of the H2Kd protein on the hybrid cells. These
translocation events would not be detected by our FISH analysis
using centromeric probes. To confirm that the mouse:human
hybrid cells did not contain any mouse DNA flow cytometry
sorted and collected H2Kd+HLA+ cells were grown in CFU
cultures that allowed the cells to undergo proliferation. Cell
proliferation will result in the loss of H2Kd antigen on the cell
surface if there is no mouse gene present to be transcribed.
H2Kd+HLA+ cells were grown in CFU medium containing either
mouse recombinant growth factors or human recombinant growth
factors for 18 days. Control unsorted BM cells from mice that did
not receive any human cells grew in medium with recombinant
Figure 4. Mouse CD14 and CD41a do not transfer to human donor cells. (Ai) A non-engrafted mouse confirms that anti-human HLA-ABC
and (Aii) anti human CD14 antibodies do not cross react with mouse cells. (Aiii) Anti-mouse CD14 identifies mouse macrophages in the bone marrow.
(Bi) Bone marrow from an engrafted mouse contains a high percentage of human cells (HLA+) that are also H2Kd+. (Bii) Human CD14+ cells are also
H2Kd+, confirming the transfer of H2Kd to human macrophages and (Biii) the absence of HLA+ cells co-expressing mouse CD14 indicates that unlike
H2Kd and CD45, CD14 is not involved in trogocytosis. (Ci) In order to test the involvement of platelets in trogocytosis we tested for the transfer of
CD41a. Bone marrow from a non-engrafted mouse stained with anti-HLA antibody and anti mouseCD41a antibody was negative for HLA but
demonstrated that 5% of all bone marrow cells are mouse CD41a positive. (Cii) Bone marrow from the same engrafted mouse as used for CD14
detection reveals that the bone marrow was negative for human CD41a, indicating human platelets are not produced in NOD/SCID mouse. (Ciii) The
absence of HLA+ cells co-expressing mouse CD41a confirms that CD41a is also not involved in trogocytosis.
doi:10.1371/journal.pone.0008489.g004
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human UCB cells grew in both media (n=2, each condition).
Mouse-derived H2Kd+HLA+ cells were collected from mice at
2 weeks, 4 months or 5 months post-engraftment (n=2, each
condition). The hybrid cell displayed the same CFU growth
properties as the human control cells. They grew well in media
containing human growth factors or mouse growth factors,
supporting the hypothesis that the cells contain only human
DNA (Table 1). Furthermore, the cells from the hybrid-cell CFUs
were collected post culture and stained with anti-HLA antibody
and anti-H2Kd antibody. The cells were only positive for the
human antigen (HLA+H2Kd-) having lost the H2Kd protein
during cell culture (data not shown). Therefore culture resulted in
the loss of the H2Kd protein as would be expected if the cells did
not contain any mouse DNA.
In order to confirm the involvement of donor stem and early
progenitor cells, H2Kd+/HLA+ blood cells were collected from
the bone marrow of engrafted mice (2 months post transplantation
with UCB) and tested in a Long-Term Culture-Initiating Cell
(LTC-IC) assay for the detection of stem/early progenitor cells
(n=2, each cell sample). Control cells included Lin- UCB cells
Figure 5. Trogocytosis occurs in the bone marrow and involves CD34+ cells. Peripheral blood from animals engrafted with Lineage
negative (Lin-) or total nucleated cells (TNC) were double positive for human HLA and mouse H2Kd after 1 month post transplantation. Since the
bone marrow but not the peripheral blood of day 7 and day 9 mice were positive for hybrid cells (compare to Figure 1), this suggests the human
donor cells must first migrate to the bone marrow and engraft before trogocytosis can occur. Mice that received Lineage positive (Lin+) did not
display hybrid cells. (Bi) CD34+ human cells make up a small population of engrafted cells (0.14%) but over 89% of them are also H2Kd+ indicating
trogocytosis involves hematopoietic stem and progenitor cells.
doi:10.1371/journal.pone.0008489.g005
Table 1. Hybrid cell contain blood progenitor cells as
demonstrated by positive CFU growth.
CONTROLS H4344* M3434*
Mouse BM 0 23
Human UCB 44 28
HLA+/H2Kd+
2weeks 28 15
4 months 40 65.5
5 months 29.5 35
*Colonies per 5000 cells/plate n=2
Human blood cells are capable of forming colonies in medium containing
human or mouse growth factors, while mouse blood cells are only capable of
surviving in medium containing mouse growth factors. Hybrid cells (HLA+/
H2Kd+) demonstrate growth characteristics of human blood progenitor cells.
Cells from these CFUs were collected after 18 days in culture and stained for
flow cytometry analysis with anti-H2Kd antibody. All cells that were originally
H2Kd+/HLA+ at the beginning of the CFU culture lost the H2Kd antigen after
the culture period indicating that the cells did not contain the H2Kd gene.
doi:10.1371/journal.pone.0008489.t001
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colonies/plate. H2Kd+/HLA+ cells produced 81 and 87 colonies
per 1610
5 cells /LTC-IC assay. The presence of LTC-IC positive
colonies from the H2Kd+/HLA+ bone marrow cells indicates
trogocytosis includes the stem/progenitor cells.
Although CD34+ donor cells acquired H2Kd antigen on their
surface the CFU-FACS experiment suggests that it is unlikely
that CD34+ cells were able to retain the mouse antigens on their
surface throughout cell proliferation and maturation. Taken
together our data demonstrates that trogocytosis is an ongoing
event that occurs in the bone marrow and the long-term
engraftment of human blood stem cells in the mouse bone
marrow provides for a constant supply of progenitor and
maturing human blood cells that are involved in trogocytosis,
which is why we can observe hybrid cells 7 months post
engraftment.
Studies of Chimera Animals Reveal That Blood Cell
Trogocytosis Is Enhanced by the Irradiation Pre-
treatment of Recipient Mice During Bone Marrow
Transplantation
Previous studies have demonstrated that trogocytosis occurs
during the formation of the immune synapse during routine
immune cell interactions [26]. We have demonstrated that during
bone marrow transplantation using an irradiation pre-condition-
ing the frequency of trogocytosis and the different types of cells
involved greatly increases. In order to determine if trogocytosis
between blood cells is a result of the irradiation pre-conditioning,
we generated chimeric animals from two strains of mice with
different MHC haplotypes. C57BL/6 ES cells (H2Kb) marked
with enhanced green fluorescent protein (EGFP) transgene
(C57BL/6-EGFP) and BALB/c mice (H2Kd). This study allowed
for the production of animals with mixed HLA type blood cells
without using irradiation. Thus, positive trogocytosis was deter-
mined by the presence of EGFP+/H2Kd + cells. Three chimeric
mice were chosen based on their range of coat colour chimerism
which was 30%, 50% and 80% respectively. Blood cell analysis for
all three mice is depicted in Figure 6A. Blood cells and cells from
tissues in the chimeric mice displayed a wide range of EGFP signal
intensities. In order to detect the low and high expressing cells the
voltage for the FACS detector was set to detect and display both
low EGFP and high EGFP signals at the expense of keeping the
negative cells on the Y-axis (see Materials and Methods for voltage
settings). Original FACS plots with percentages of cells are shown
along with pictomicrograph representation for positive (weak to
strong expressing cells represented in the right side quadrants).
IgG-PE isotype control is represented in Figure 6Ai,ii,iii. Note that
EGFP cells can be observed in the IgG-PE isotype control and
gives us a clear indication of the chimera contribution from the
C57BL/6 blood cells. The blood cell chimerism does not reflect
the coat colour chimerism with mice having 51%, 83% and 82.3%
C57BL/6-EGFP blood cell contribution, respectively. We did
observe hybrid EGFP+H2Kd+ cells, ranging from 13.3% to
16.4% of the total blood cells (Figures 6Aiv,v, vi). This experiment
supports data from the literature stating trogocytosis occurs
naturally, with this experiment specifically demonstrating involve-
ment of the class I MHC(H2Kd) antigens. The frequency of
trogocytosis in the blood of these chimeras is lower than in the
xenograft studies but within the range expected for the previously
described role for trogocytosis involvement in immune surveil-
lance. This data indicates that preconditioning radiation used in
the bone marrow transplant studies may increase the number of
cells involved in trogocytosis.
Trogocytosis Occurs among Non-Blood Cells of the Solid
Organs
Since our data has revealed that trogocytosis is more wide
spread than previously reported, we sought to investigate if
trogocytosis extends to non-blood tissues. The same chimeric
animals analysed for blood-based trogocytosis in the previous
section were further analysed for non-blood tissue based
trogocytosis. Chimeric organs were divided and a portion was
fixed for immunohistochemistry while the remaining tissue was
treated with collagenase to generate single cells for flow cytometry
analysis. Cells were stained for flow cytometry with anti mouse
CD45antibody and anti H2Kd antibody. The CD45 antibody
allowed us to remove any contaminating blood cells (CD45+) and
CD45 negative cells were then analysed for EGFP and H2Kd.
The same cytometry settings were used here as used for the blood
cell analysis. Figure 6B and the accompanying Table 2 are
representative from mouse #2 (50% coat colour chimerism and
80% blood cell chimerism). The total organ chimerism (% EGFP
positive cells) is listed in Table 2 column 1 and the percentages of
trogocytosis positive cells are listed in column 2. Trogocytosis
positive cells from the non-blood organs (EGFP+/H2Kd+/CD45-)
ranged from 1.0% of total EGFP+ cells in the spinal cord to 58%
in the lung. However, we cannot determine from this experiment if
the transferred H2Kd proteins that came from the BALB/c
contribution was from the circulating blood cells or from the
BALB/c cells within the organ. Closer examination of the results
indicates that organs with high blood circulation such as the liver,
lungs and heart have a higher percentage of EGFP cells co-
expressing H2Kd then other tissues indicating a higher frequency
of trogocytosis events. For example only 2% of the liver cells are
EGFP+ (low chimerism) but 50% of these cells are also positive for
H2Kd (high trogocytosis). In contrast, the spinal cord contained
33% EGFP+ cells (high chimerism) but only 1% co-expressed
H2Kd and EGFP+ (low trogocytosis). These data suggests that
blood cells are the source of the H2Kd antigen to the cells of
organs.
Analysis of the tissue sections from the chimeric mice confirms
our flow cytometry results. Tissue sections were stained with an
anti H2Kd antibody. Distinct boundaries between clonal contri-
butions from the two different mouse strains are visible for
intestine, liver and lung (Figure 7A-D). Distinct patches of yellow
cells, resulting from the surface staining of transferred H2Kd with
a red secondary antibody (Alexaflour 596) combined with green
(EGFP+) cytoplasm, were observed in tissue sections indicative of
the transfer of H2Kd to EGFP cells in the liver and the lung
(Figure 7B,C arrow). Chimeric lung tissue with no trogocytosis is
shown in Figure 7D.
Discussion
Bone marrow transplantation using hematopoietic stem cells is a
common procedure used to reconstitute the bone marrow and
regenerate the immune system after full or partial myeloablative
therapy to eradicate blood based cancers. Despite the widespread
use of bone marrow transplants, there have not been any studies
investigating the extent of cell fusion or trogocytosis between blood
cells of the donor and host in the transplant setting. Because of the
numerous reports of cell fusion and particularly fusion between
blood cells and non-blood cells we investigated whether blood cells
are capable of fusion with each other [13,27]. Using a standard
mouse model for hematopoietic stem cell engraftment we were
able to demonstrate that .80% of the donor cells carried recipient
surface MHC class I proteins suggesting a fusion event. Further
investigation resulted in our concluding that cell-cell fusion was
MHC Transfer in BM Transplants
PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8489Figure 6. H2Kd is transferred between blood cells and non-blood organs of chimeric mice. Chimeric mice were generated from C57BL/6
EGFP ES cell line #12 with BALB/cAnNCrl morula. (A) The mouse blood cells displayed a range of EGFP expression levels. The voltage settings for the
detectors were adjusted to clearly display the cells expressing low levels of EGFP as well as the high expressing cells, with negative cells gated close
to the Y-axis. Adjacent pictomicrographs show the percentage of cells in each quadrant. The first column (i,ii,iii) represents the IgG-PE control and
displays the EGFP+ cells. The second column (iv,v,vi) represents the same cells co-stained with H2Kd-PE. Double positive cells (H2Kd-PE+, EGFP+) are
cells that have undergone trogocytosis of the H2Kd antigen. Observations of EGFP expressing cells that also express H2Kd was demonstrated by the
shift of the population upward into the top right hand quadrant. Trogocytosis positive cells are 16.4%, 13.3% and 15.6% of the total bone marrow
cells in the three mice respectively. Control; mouse blood cells from Balb/c mouse (EGFP-). B) Tissues from chimeric mouse #2 were analysed by flow
cytometry. Tissue samples were stained with H2Kd-PE and flow cytometry was used to identify H2Kd-PE+ and EGFP+ cells. The percent chimerism for
each organ was determined by EGFP+ cells and the amount of cells involved in trogocytosis was determined as the percentage of double positive
cells (EGFP+, H2Kd-PE+) of the total EGFP+ cells. Tissues with high blood flow (heart and lung) have the highest levels of trogocytosis. The results are
summarized in Table 2.
doi:10.1371/journal.pone.0008489.g006
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nor could other mechanisms such as DNA uptake of apoptotic
bodies by phagocytosising cells. The most parsimonious mecha-
nism was trogocytosis.
The potential transfer of mismatched Class I HLA antigens
between cells as identified in this study has implications for graft
acceptance in the bone marrow transplant setting. Furthermore, in
animal studies used to investigate the ability of blood cells to
differentiate into non-blood tissues, the determination of successful
stem cell differentiation or blood cell transdifferentiation relies
heavily on the identification of cell surface markers on the
regenerated tissue. Thus, the occurrence of hybrid cells due to cell
fusion or surface antigen transfer between blood cells or blood cells
and organs needs to be clarified when interpreting differentiation
as well as transdifferentiation data. Furthermore, the recent report
that the transfer mitochondria occurs between cells without cell
fusion indicates that cell-cell interaction involves many novel
mechanisms [28].
In this study we investigated the extent of trogocytosis between
donor and recipient blood cells in the bone marrow transplant
setting and between blood cells and non-blood cells in chimeric
animals. Our study demonstrates that trogocytosis is more
common than previously reported [26]. It has been demonstrated
by others that dendritic cells, NK cells, T and B-cells are capable
of acquiring MHC class1 antigens by trogocytosis at the
immunological synapse. Here we have expanded on these studies
to investigate the occurrence of surface protein transfer in the
xenograft setting and its impact on our understanding of
experimental disease models. We have clearly demonstrated that
trogocytosis is not limited to antigen presenting cells as all donor
hematopoietic blood cells, including the CD34+ stem and
progenitor cells, acquired recipient MHC Class I molecules.
Mouse engraftment models have been the standard assay used
to identify blood stem cells. Despite the long history of using
murine models for intra-species and xenograft transplants, our
observation that almost all of the donor blood cells acquired
recipient MHC proteins in 100% of the engrafted mice, regardless
of time post transplant (t=7 days to t=7 months), has not been
previously reported. Our NOD/SCID mouse transplant protocol
results in low numbers of human antigen presenting T and NK
cells and B-cells and therefore, trogocytosis due to immune cell
reactions cannot account for all of the events observed in this study
[12,29,30,31]. Although there was not a transfer of DNA during
trogocytosis, our long-term studies and peripheral blood analysis
demonstrate that trogocytosis is an ongoing event and was
maintained in the recipient mice for 7 months. FISH analysis,
karyotyping and the loss of cell surface markers after in vitro
culturing confirmed that trogocytosis and not cell fusion was the
cause of hybrid cells in a bone marrow transplant setting.
Furthermore, using chimeric animals, we have demonstrated that
both blood and non-blood tissues are involved in trogocytosis. Our
observation that MHC-Class I antigens are involved implicates
potential role of trogocytosis in graft acceptance.
In the bone marrow transplant setting, we were able to
demonstrate that trogocytosis occurs in the bone marrow and not
the peripheral blood, where the cells find themselves in close
contact, a requirement for surface protein transfer. Therefore
trogocytosis requires that the donor cells migrate to the bone
marrow and engraft. In the clinical setting, trogocytosis would
require the presence of recipient cells, a condition that is met in
myeloablative conditioning of humans as donor cell infusion
occurs before the patient becomes aplastic. Recipient bone
morrow cells would also be present to participate in trogocytosis
in reduced intensity and non-myeloablative conditioning regimes
used for human bone marrow transplants.
Interestingly, our studies indicate that trogocytosis is unidirec-
tional for MHC-Class I antigens, with proteins moving from the
recipient cells to the donor cells. The widespread transfer of
recipient MHC class1 molecules to donor blood cells and donor
organs led us to question if other surface proteins are involved in
trogocytosis as well. Recipient (mouse) CD45, but not recipient
CD14 or CD41a, could be transferred to donor (human) cells.
These observations, along with the chimera studies, demonstrate
MHC Class I molecules are routinely transferred in the transplant
setting, as are CD45 antigens, although the latter occurs to a lesser
extent. Despite the fact that donor stem and progenitor cells
(CD34+) are involved in trogocytosis, it is unlikely that these cells
are the sole source of hybrid cells. Hematopoietic cells undergo
extensive cell division before moving into the circulation and it is
unlikely any recipient proteins acquired by trogocytosis at the stem
cell level would be present on mature cells.
It has also been demonstrated by others that trogocytosis results
in the transfer of proteins that can maintain their function on the
receiving cells. For example, there is evidence that HLA-G can be
transferred from a tumour cell to a healthy cell, conferring the
same NK cell suppression function that it had on the tumour
cell[32] and T-cells that acquired CD80 and HLA-DR from
antigen presenting cells developed an antigen presenting-cell
function [33]. The demonstration that HLA-G or CD80/HLA-
DR transfer results in the establishment of function suggests that
the transfer of MHC class I proteins from the recipient cells to the
donor cells observed in our study may alter the way the donor cell
is perceived by the host immune system [34]. We can speculate
that the transfer of recipient MHC could confer a ‘recipient-self’
identity to the donor cells, thus protecting them from immune
attack in the bone marrow transplant setting. Support for this
hypothesis comes from the demonstration that the genetic
regulation of NK cell-mediated rejection of bone marrow grafts
is dependent on the MHC class I genes. It has been demonstrated
Table 2. The percentage of cells involved in trogocytosis
varies with the organ and is not related to the extent of tissue
chimerism.
Tissue % Tissue Chimera
a % Trogocytosis
b









Spinal Cord 33 1
Testes 53 5
Trogocytosis positive cells are identified as cells expressing the EGFP gene and
the H2Kd gene. The extent of trogocytosis varies widely amongst the different
organs and is more frequent in organs that have high blood flow. This
experiment shows trogocytosis in only the one direction (Balb/c to C57Bl/6).
a) Chimerism is based on the percentage of EGFP+ cells.
b) Trogocytosis can only be observed by the transfer of H2Kd (red) onto EGFP+
(green) cells. The percent of double positive cells is based on the total of EGFP+
cells.
doi:10.1371/journal.pone.0008489.t002
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‘self’ MHC recognised by the recipient NK cells. In one study, it
was demonstrated that the introduction of a single transgene of the
recipient MHC-class I gene into mismatched donor bone marrow
cells resulted in the donor cells being able to present as ‘self’ MHC
in the recipient, thereby altering the reaction of NK cells and
preventing rejection [34].
Blood cells have therapeutic potential beyond the reconstitution
of the bone marrow. Using different animal models of human
disease, blood cells have been shown to give rise to neural cells,
endothelial cells, striated muscle, hepatocytes and cardiac
tissue[35,36,37]. It has been suggested that blood cells have the
ability to transdifferentiate due to their ability to give rise to non-
blood cells such as cardiomyocytes [38] or hepatocytes [3] while
other studies have demonstrated that putative transdifferentiation
events are actually a result of cell-cell fusion [23,27]. Transdiffer-
entiation-like events can also be linked to the possible presence of a
rare pluripotent embryonic-like stem cell in the blood [39]. While
it is possible that transdifferentiation events can be due to one or
all of these mechanisms our study indicates that trogocytosis may
account for some putative transdifferentiation events involving
blood cells.
The chimera mouse model is ideal for the study of trogocytosis
as there have been no reports of cell fusion in chimeras [40].
Furthermore, cell fusion that has been observed in the liver
between hepatocytes and blood cells is initiated by tissue damage
[41]. The lack of any induction of tissue damage in our chimera
experiments allowed us to observe trogocytosis only. The data
from the chimera studies suggests that blood flow within an organ
and not the level of organ chimerism dictates the frequency of
trogocytosis as organs with high blood flow had high levels of
trogocytosis despite their levels of chimerism. For example liver
had only 2% chimerism (2% EGFP+ cells) but 50% of these cells
were involved in trogocytosis (EGFP+/H2Kd+) versus the spinal
cord with 33% chimerism but only 1% of these cells were also
H2Kd+.
Figure 7. Trogocytosis in solid organs is observed in chimeric animals. A) Intestine, B) liver and (C and D) lung tissues, display distinct clonal
boundaries between BALB/c and C57BL/6 cells. EGFP cells of C57BL/6 origin are green in colour while the H2Kd BALB/c cells are red. EGFP cells that
have acquired H2Kd result in a yellow signal (white arrow). Scale bar=50 mm
doi:10.1371/journal.pone.0008489.g007
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mechanism to consider for normal immune reactions, organ and




Collection of all human tissue samples were approved by the
Research Ethics Boards of the University of Toronto and Mount
Sinai Hospital, Toronto, Canada. Patients were required to read a
patient information sheet and sign a consent form prior to any
samples being collected. All samples were anonymous.
All animal studies were approved by the animal ethics board at
Mount Sinai Hospital (AUP# 09-12-0021a-H).
Blood Collection, Processing and Cryopreservation
Qualified hospital personnel, following protocols approved by
the human ethics committee of the Mt. Sinai Hospital and the
University of Toronto, collected the cord blood at the time of
delivery. The BM or UCB samples were screened for HIV I/II,
HTLV-I/II, Hepatitis B (HBs Ag), Hepatitis C (anti HVC), CMV
and VDRL and written consent for collecting and processing
umbilical cord blood was obtained at the time of registration.
The blood volume was reduced and the red blood cells removed
with Pentaspan (starch) (DuPont, USA) as described previously
[37]. All samples were cryopreserved prior to use by storage in
liquid nitrogen.
Isolation of an Enriched Stem Cell or Progenitor Cell
Population
Human UCB or BM were used fresh or thawed and diluted
drop wise in 106volume, pelleted and resuspended in 0.1% BSA/
HBSS. Lin- cells were isolated using a negative selection column
according to the manufacturer’s instructions (StemCell Technol-
ogies, Canada). The antibody mix contained a set of lineage
specific surface markers found on mature hematopoietic cells;
CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66 and
glycophorin A. Following isolation, the Lin- cells or the Lin+ cells
were used directly in the SRC-assay.
Long Term Cell-Initiating Cell Assay (LTC-IC)
Repopulating Assay and Colony Forming Unit Assay
(CFU)
A pre-made methylcellulose based colony assay medium (Stem
Cell Technologies, Canada) was used as described by the
manufacturer. The medium is formatted to grow mouse
(M3434) or human (H4344) primitive progenitors. Total nucleated
cells from bone marrow aspirates were stained with antibodies to
H2Kd and HLA-ABC and sorted by flow cytometry. Sorted cells
were plated at 5000 and 2000 cells per 3 ml of medium. All
populations were plated in duplicate and scored at days 12, 14, 16
and 18. Day 16 data is represented in Table 1. Cells were also
tested for primitive progenitor cells by LTC-IC protocol as
described by the manufacturer (Stem Cell Technologies, Canada).
Briefly, cells were plated on M2-10B4 fibroblasts (Stem Cell
Technologies, Canada) and cultured for 5 weeks with half medium
changes weekly. Cells were then collected and plated in a CFU
assay (H4344) and scored at day 18 for colonies.
NOD.CB17-Prkdc
SCID Mouse Engraftment
Non-obese severe combined immune deficient NOD.CB17-
Prkdc
SCID mice (Jackson Labs, Bar Harbour, Maine, USA) were
used to test the engraftment potential of human blood cells [24].
All experiments followed established protocols and received
animal ethics approval at Mt. Sinai Hospital. The mice were
irradiated 2 hours before engraftment at 360 Rads using a Cs
137
source. The mice were then injected via the tail vein with 100 mlo f
cell solution. Survival rate was .80% per experiment. At different
time intervals, animals were euthanized and the bone marrow was
flushed from the femurs. Cells were washed in PBS and the cell
pellets were subjected to Red Blood Cell Lysis Buffer for 3 minutes
and washed again.
Flow Cytometry
A: Bone marrow analysis. Mice were sacrificed from
7 days to 7 months post transplantation, the femurs excised
and flushed using 1 ml of PBS containing 2% FBS (2% FBS/
PBS). Cells were treated with RBC Lysis Buffer and washed
once with 2% FBS/PBS and pelleted. The cell pellet was
resuspended at 1 million cells/ml and immunostained. After the
antibody was added, cells were incubated on ice for 30 min.
washed twice in 2% FBS/PBS and resuspended at 1 million cells
per 0.2 ml and immediately analysed by flow cytometry with a
Coulter-Epics Flow cytometer (Coulter, Burlington, Canada).
Isotype controls were used in all cases. Peripheral blood was
collected for analysis by heart p u n c t u r eb e f o r eb o n em a r r o ww a s
collection.
B: Chimera analysis. To generate single cell suspensions
from mouse organs, mice were perfused with 5% FBS/HBSS and
the organs dissected and minced on ice. These minced tissues were
washed with PBS and incubated at 37uC in an enzyme solution
containing 1.5 mg/ml collagenase + 0.25% trypsin in PBS for 10–
30 minutes depending on the size of the tissue fragment. After
incubation, DMEM containing 5% FBS was added to the tissues
that were then triturated with a large bore pipette so not to shred
the cells. The large fragments were allowed to settle (30 sec) and
the single cells in suspension were collected. This single cell
suspension was passed through a 70 micron mesh filter and at this
point was ready for FACS immunostaining as outlined above. The
range of EGFP fluorescence intensity in chimeric mice was
variable, so in order to clearly display the full range of EGFP
expressing cells required that the detectors for EGFP were set to
capture and display all EGFP positive cells at the expense of the
negative cells being pushed up against the Y-axis. Original
histograms displaying percentages of cells for each quadrant are
shown in the figures. The settings for the detectors are shown in
Table 3.
Antibodies
Primary antibodies used: H2Kd (BD-Pharmingen, USA), mouse
CD45 (BD-Pharmingen, USA), human CD45 (J33) (Immunotech,
France), HLA-ABC (Immunotech, France), human CD34 (Im-
munotech, France), mouse CD14 (BD-Pharmingen, USA), human
CD14 (Immunotech, France), mouse CD41a (BD-Pharmingen,
USA), human CD41a (BD-Pharmingen, USA). Secondary anti-
bodies conjugated with Alexafluor 596 (Red) or Alexafluor 488
(Green) were used.
Fluorescent In-Situ Hybridization
Pan centromeric chromosome paint for human (cat# 1695) and
mouse (cat# 1697) from StarFISH (Cambio, England) was used
for fluorescent in-situ hybridization (FISH). Cells were fixed in 3:1
ethanol:acetic acid, dehydrated in an ethanol series, mounted on
slides and air dried FISH was performed according to the
manufacturer’s protocol (StarFISH, Cambio, England).
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Fluorescent variants of C2-C57BL/6NTac ES cells were
generated by the random integration of EGFP transgene driven
by a CMV immediate early enhancer coupled to the chicken b-
actin promoter and first intron (pCAG) using co-electroporation
with a circular selectable marker pPGK Puro using standard ES
cell culture protocols[42]. Chimeric mice were produced by
aggregation of C57BL/6 EGFP ES cell line #12 with BALB/
cAnNCrl morula stage embryos as described[42,43]. Chimeras
were identified by a mixed black and albino coat colour. Chimeras
were sacrificed at 8-weeks of age and tissues were processed for
immunohistochemistry or flow cytometry.
Immunohistochemistry
Tissues were fixed in 10% buffered formalin (Fisher Scientific, USA)
for 120 min, at 4uC, washed in PBS (Phosphate Buffered Saline),
stored in 70% ethanol, dehydrated in graded ethanol series, cleared in
toluene, immersed in paraffin at 65uC, embedded into paraffin blocks
and sectioned into 5 mm sections. Sections were deparaffinized
265 min in xylene. Nonspecific binding was blocked with 10% serum
in PBS containing 0.1% Triton X-100 (Sigma, USA) for 240 min at
room temperature, followed by a brief wash in PBS. Primary antibody
was applied (solution 1:50–1:100) for overnight incubation at 4uC.
Untreated mouse tissue sections and sections with omitted primary or
secondary antibody were used as negative controls. The slides were
washed 5615min in PBS, the secondary antibody was applied at 1:200
dilution for 60 min at room temperature, and then washed again
6615 min in PBS. Finally, the slides were mounted in 50% glycerol in
PBS with DABCO (Sigma, USA) at 100 mg/ml.
The slides were examined on a Zeiss Axioplan Photomicroscope
equipped with epifluorescent ultraviolet light and corresponding
excitation and barrier filters. Pictures were taken on a Delta Vision
wide-field, optical sectioning microscope workstation capable of
recording three-dimensional images of fluorescently labelled
specimens (Issaquah, Washington). The station includes: an
Olympus IX-70 inverted fluorescence microscope with custom
optical filters, and precision XYZ motorized stage, O2 Silicon
Graphics computer work station with image collection and
deconvolution software.
Supporting Information
Figure S1 Confirmation of the specificity of the antibodies used
for FACS analysis.
Found at: doi:10.1371/journal.pone.0008489.s001 (0.96 MB TIF)
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